Literature DB >> 17400613

Financial incentives for antipsychotic depot medication: ethical issues.

Dirk Claassen1.   

Abstract

BACKGROUND: Giving money as a direct incentive for patients in exchange for depot medication has proved beneficial in some clinical cases in assertive outreach (AO). However, ethical concerns around this practice have been raised, and will be analysed in more detail here.
METHOD: Ethical concern voiced in a survey of all AO teams in England were analysed regarding their content. These were grouped into categories.
RESULTS: 53 of 70 team managers mentioned concerns, many of them serious and expressing a negative attitude towards giving money for depot adherence. Four broad categories of ethical concern following Christensen's concept were distinguished: valid consent and refusal (n = 5), psychiatric paternalism (n = 31), resource allocation (n = 4), organisational relationships (n = 2), with a residual category others and unspecified (n = 11). DISCUSSION: The main concerns identified are discussed on the background of existing ethical theories in healthcare and the specific problems of community mental health and AO. Points for practice are derived from this discussion. A way forward is outlined that includes informed consent and an operational policy in the use of incentives, further randomised controlled trials and qualitative studies, and continuing discussions with all stakeholders, especially service users.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17400613      PMCID: PMC2652785          DOI: 10.1136/jme.2006.016188

Source DB:  PubMed          Journal:  J Med Ethics        ISSN: 0306-6800            Impact factor:   2.903


  13 in total

Review 1.  Special section on involuntary outpatient commitment: introduction.

Authors:  M S Swartz; J Monahan
Journal:  Psychiatr Serv       Date:  2001-03       Impact factor: 3.084

2.  A phenomenological account of users' experiences of assertive community treatment.

Authors:  Jay Watts; Stefan Priebe
Journal:  Bioethics       Date:  2002-09       Impact factor: 1.898

3.  Methods and principles in biomedical ethics.

Authors:  T L Beauchamp
Journal:  J Med Ethics       Date:  2003-10       Impact factor: 2.903

4.  Ethics of assertive outreach (assertive community treatment teams).

Authors:  Toby Williamson
Journal:  Curr Opin Psychiatry       Date:  2002-09       Impact factor: 4.741

5.  Ethics of community psychiatry.

Authors:  G Adshead
Journal:  Curr Opin Psychiatry       Date:  1999-09       Impact factor: 4.741

6.  An ethical framework for psychiatry.

Authors:  Sidney Bloch; Stephen A Green
Journal:  Br J Psychiatry       Date:  2006-01       Impact factor: 9.319

7.  Ethical issues in community mental health: cases and conflicts.

Authors:  R C Christensen
Journal:  Community Ment Health J       Date:  1997-02

8.  Use of leverage to improve adherence to psychiatric treatment in the community.

Authors:  John Monahan; Allison D Redlich; Jeffrey Swanson; Pamela Clark Robbins; Paul S Appelbaum; John Petrila; Henry J Steadman; Marvin Swartz; Beth Angell; Dale E McNiel
Journal:  Psychiatr Serv       Date:  2005-01       Impact factor: 3.084

9.  Mandated community treatment: beyond outpatient commitment.

Authors:  J Monahan; R J Bonnie; P S Appelbaum; P S Hyde; H J Steadman; M S Swartz
Journal:  Psychiatr Serv       Date:  2001-09       Impact factor: 3.084

10.  The REACT study: randomised evaluation of assertive community treatment in north London.

Authors:  Helen Killaspy; Paul Bebbington; Robert Blizard; Sonia Johnson; Fiona Nolan; Stephen Pilling; Michael King
Journal:  BMJ       Date:  2006-03-16
View more
  14 in total

Review 1.  Tactics and technologies to manage nonadherence in patients with schizophrenia.

Authors:  William M Glazer; Mathew J Byerly
Journal:  Curr Psychiatry Rep       Date:  2008-08       Impact factor: 5.285

Review 2.  Using incentives to reduce substance use and other health risk behaviors among people with serious mental illness.

Authors:  Jennifer W Tidey
Journal:  Prev Med       Date:  2011-12-09       Impact factor: 4.018

3.  Laypersons' views of material incentives for enhancing colorectal cancer screening.

Authors:  Lea Hagoel; Gad Rennert; Paula Feder-Bubis
Journal:  Health Expect       Date:  2013-06-10       Impact factor: 3.377

4.  Financial incentives to encourage healthy behaviour: an analysis of U.K. media coverage.

Authors:  Hannah Parke; Richard Ashcroft; Rebecca Brown; Theresa M Marteau; Clive Seale
Journal:  Health Expect       Date:  2011-07-20       Impact factor: 3.377

5.  Can incentives improve antipsychotic adherence in major mental illness? A mixed-methods systematic review.

Authors:  Nathan Hodson; Madiha Majid; Ivo Vlaev; Swaran Preet Singh
Journal:  BMJ Open       Date:  2022-06-15       Impact factor: 3.006

6.  Acceptability of offering financial incentives to achieve medication adherence in patients with severe mental illness: a focus group study.

Authors:  Stefan Priebe; Julia Sinclair; Alexandra Burton; Stamatina Marougka; John Larsen; Mike Firn; Richard Ashcroft
Journal:  J Med Ethics       Date:  2010-06-27       Impact factor: 2.903

Review 7.  The impact of incentives on exercise behavior: a systematic review of randomized controlled trials.

Authors:  Kelley Strohacker; Omar Galarraga; David M Williams
Journal:  Ann Behav Med       Date:  2014-08

8.  Long-acting injectable antipsychotics for first-episode schizophrenia: the pros and cons.

Authors:  Borah Kim; Sang-Hyuk Lee; Yen Kuang Yang; Jong-Il Park; Young-Chul Chung
Journal:  Schizophr Res Treatment       Date:  2012-08-14

9.  Personal financial incentives in health promotion: where do they fit in an ethic of autonomy?

Authors:  Richard E Ashcroft
Journal:  Health Expect       Date:  2011-02-23       Impact factor: 3.377

10.  Financial incentives to improve adherence to anti-psychotic maintenance medication in non-adherent patients - a cluster randomised controlled trial (FIAT).

Authors:  Stefan Priebe; Alexandra Burton; Deborah Ashby; Richard Ashcroft; Tom Burns; Anthony David; Sandra Eldridge; Mike Firn; Martin Knapp; Rose McCabe
Journal:  BMC Psychiatry       Date:  2009-09-28       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.